Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$200.47 USD

200.47
3,531,078

-3.08 (-1.51%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $200.75 +0.28 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales

by Zacks Equity Research

Biogen (BIIB) beats estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.

Why Earnings Season Could Be Great for AbbVie (ABBV)

by Zacks Equity Research

AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Beat in Store for AbbVie (ABBV) This Earnings Season?

by Zacks Equity Research

Strong growth of Imbruvica and Mavyret are expected to drive AbbVie (ABBV) first-quarter sales. Declining ex-U.S. Humira sales are likely to be an overhang on the top line.

Biogen (BIIB) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

While sales of Biogen's (BIIB) MS franchise are expected to decline in the first quarter of 2019 that of Spinraza are likely to increase.

Sweta Killa headshot

Can Q1 Earnings Lift Healthcare ETFs Higher?

by Sweta Killa

With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.

AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

AbbVie (ABBV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here Are the Key Takeaways From J&J's Q1 Earnings Report

by Zacks Equity Research

Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.

J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View

by Zacks Equity Research

J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.

AbbVie (ABBV) Gains As Market Dips: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed at $81.01 in the latest trading session, marking a +0.28% move from the prior day.

J&J (JNJ) to Kick-start Pharma Q1 Earnings: What's in Store?

by Zacks Equity Research

J&J's (JNJ) sales growth in first-quarter 2019 is expected to be hurt by generic/biosimilar headwinds in the Pharma unit.

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, AbbVie (ABBV) closed at $83.98, marking a +0.64% move from the previous day.

J&J Stock on an Uptrend This Year So Far: More Room to Run?

by Zacks Equity Research

J&J (JNJ) performs better than the industry in 2019 so far and looks well poised to sustain the momentum in the rest of the year.

Mark Vickery headshot

Top Stock Reports for Boeing, Lockheed Martin & Anthem

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), Lockheed Martin (LMT) and Anthem (ANTM).

Novartis Resubmits BLA to FDA for Biosimilar of Neulasta

by Zacks Equity Research

Novartis' (NVS) generic arm Sandoz resubmits its BLA for the proposed biosimilar of Neulasta.

Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003

by Zacks Equity Research

Alector, Inc. (ALEC) initiates the phase I INTERCEPT study on AL003 for the treatment of Alzheimer???s disease.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed at $80.76 in the latest trading session, marking a +0.2% move from the prior day.

Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals

by Zacks Equity Research

AstraZeneca announces a $6.9 billion cancer deal with Daiichi Sankyo. AbbVie (ABBV), Novartis (NVS) & AstraZeneca's (AZN) drugs get regulatory approvals.

Gilead & Galapagos Announce Positive Data on Arthritis Drug

by Zacks Equity Research

Gilead (GILD) and partner Galapagos announce positive results from late-stage studies on investigational drug, filgotinib for the treatment of RA.

AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan

by Zacks Equity Research

AbbVie's (ABBV) psoriasis drug Skyrizi gains the maiden approval in Japan for treating adults with plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis.

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed the most recent trading day at $79.64, moving -0.15% from the previous trading session.

This is Why AbbVie (ABBV) is a Great Dividend Stock

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA

by Zacks Equity Research

FDA places a partial clinical hold on all studies evaluating AbbVie's (ABBV) Venclexta (venetoclax) for the treatment of multiple myeloma.

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed at $80.65 in the latest trading session, marking a -0.85% move from the prior day.

Roche Receives EC Approval for Label Expansion of Hemlibra

by Zacks Equity Research

Roche (RHHBY) gets approval from European Commission for a label expansion of hemophilia drug, Hemlibra.

Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study

by Zacks Equity Research

Theravance (TBPH) commences phase IIb/III study for its gut-selective pan- JAK inhibitor, TD-1473 in patients with moderately to severely active ulcerative colitis.